Palogic Value Management discloses 6.7% stake in Health Catalyst
Palogic Value Management, LP, Palogic Value Fund, LP, Palogic Capital Management, LLC, and Ryan L. Vardeman disclosed aggregate ownership of 4,918,866 shares, or 6.7% of Health Catalyst's common stock, crossing the reporting threshold on June 12, 2026. On June 22, 2026, Palogic Value Management sent a letter to the company expressing support for the appointment of Ben Albert as CEO and the announced divestiture of VitalWare. The reporting persons stated they intend to engage in discussions with management, the board, and other shareholders regarding performance, strategic direction, capital allocation, board composition, and governance, and reserved the right to consider additional securities transactions, extraordinary corporate transactions, asset sales, board or management changes, and other actions depending on future circumstances.
Key facts
- Palogic Value Management, LP and affiliated entities hold 4,918,866 shares, 6.7% of class
- Reporting threshold crossed June 12, 2026
- June 22, 2026 letter expressing support for CEO Ben Albert and VitalWare divestiture
- Reporting persons may engage in discussions with management, board, and shareholders on strategic matters
- Reporting persons reserved right to acquire or dispose of additional securities, pursue extraordinary corporate transactions, or seek board/management changes
Why it matters
Palogic has crossed a 6.7% stake and signaled intent to engage with Health Catalyst's board and management on strategic matters, positioning itself as an engaged shareholder with potential influence over the company's direction.
Share
Derived from SCHEDULE 13D filed 2026-06-22. Not investment advice. View the source filing on SEC.gov →